secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2023-12-11T23:59:59+00:00
Accession:  0000950170-23-069193
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo completes IPO raising $111.5M; Q3 net loss $20.1M as programs advance
---------------------------------------------------------------------------

- IPO in November 2023 raised $111.5M gross; pro forma cash $136.4M, funding operations into Q4 2025.
- Completed enrollment of all four cohorts in LEAD Phase 1/2 trial of LX1001 for APOE4-Alzheimer's.
- Received Canadian CTA clearance for LX2006 (FA cardiomyopathy); first non-US site activated.
- Net loss Q3 2023: $20.1M ($12.36 per share) vs $17.1M ($10.38) in Q3 2022; R&D spend $17.2M.
- Sandi See Tai, M.D. joined as SVP Clinical Development and Operations in October 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000095017023069193/0000950170-23-069193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000095017023069193/lxeo-20231211.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-069193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer